BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BrachySciences And Envisioneering Medical Technology Release: Agreement Brings Prostate Cancer Advancement To U.S. Market


3/28/2006 12:07:26 PM

ST. LOUIS, March 28 /PRNewswire/ -- New technology for improving prostate cancer treatment is now available to doctors nationwide through an agreement between TargetScan(R)-- developer Envisioneering Medical Technologies, based in St. Louis, and BrachySciences of Oxford, Conn.

Envisioneering's TargetScan brings together 3-D imaging and stationary probe design to improve brachytherapy treatment outcomes via more precise radioactive seed placements. Developed in partnership with Washington University School of Medicine-affiliated physicians in St. Louis, TargetScan will now be distributed to radiation oncologists through an exclusive distribution agreement with BrachySciences. The partnership calls for BrachySciences, maker and marketer of brachytherapy seed products and services, to introduce TargetScan and its patient benefits to more than 1,500 radiation oncologists and urologists who perform brachytherapy procedures throughout the United States, Canada and Puerto Rico.

"This agreement places new technology that can improve prostate cancer treatment outcomes directly in the hands of doctors to benefit their patients," said Robert G. Mills, Envisioneering president. "Radiation oncologists and urologists who use TargetScan report greater treatment success, improved patient comfort and reduced risks of post-treatment side effects, like incontinence and sexual dysfunction."

According to Mills, TargetScan represents the first system to address the unmet treatment planning and brachytherapy seed placement needs of radiation oncologists. Unlike conventional devices, TargetScan provides physicians with a stationary probe to eliminate prostate movement during treatments and reduce procedure times. The device also offers improved 3-dimensional imaging, with views of both sagittal and transverse planes, to ensure that the brachytherapy radioactive seed implants are accurately placed at physicians' pre-planned targets.

"The partnership with Envisioneering allows our company to advance its mission of providing brachytherapists with the most innovative technologies for improving prostate brachytherapy implants," said Jim Matons, BrachySciences president. "We are delighted to have signed an exclusive distribution agreement with Envisioneering as we believe TargetScan represents a major step forward in prostate ultrasound technology."

Until now, only a select group of physicians have conducted prostate cancer brachytherapy procedures using TargetScan. The director of clinical research for the Seattle Prostate Institute, Dr. Peter Grimm, regards this technology as the new standard of care for mapping, targeting and documenting treatment. "By using TargetScan we now have certainty; knowing that our treatment deliveries are accurate and that we've done everything possible to help our patients," noted Grimm.

Dr. Jeff Michalski, clinical director of the department of radiation oncology at Washington University School of Medicine in St. Louis, has been using TargetScan for eight months. Michalski found that eliminating the need to physically move the probe improves his procedures. "A stabilized prostate position allows for improved radioactive seed implantation and better brachytherapy clinical outcomes," he added.

The American Cancer Society estimates that this year will result in 234,460 new prostate cancer cases and an estimated 27,350 male deaths. Prostate cancer is the second-leading cause of cancer deaths in men behind lung cancer.

About Envisioneering Medical Technology

Based in St. Louis, Mo., Envisioneering Medical Technologies is dedicated to developing, manufacturing and marketing proprietary diagnostic and treatment technology for the physician community. For more information, please visit http://www.envisioneeringmedical.com .

About BrachySciences, Inc.

Based in Oxford, Conn., BrachySciences is committed to optimize the quality and efficiency of prostate brachytherapy implants by providing state of the art, quality brachytherapy products, and innovative technologies and services to the physicians and institutions that treat patients diagnosed with prostate cancer. For more information please visit http://www.brachysciences.com .

Envisioneering Medical Technology

CONTACT: Cheri Winchester for Envisioneering Medical Technology,+1-636-530-1235 x 223, cwinchester@commongroundpr.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES